In recent years there has been a movement to focus on attempts to detect myeloma early, and determine when to treat to prevent debilitating organ destruction.  The infamous multiple myeloma organ damage is referred to as CRAB (High Calcium, Renal damage, Anemia, and Bone Destruction).   My first thought is CRAB is not descriptive enough[...]

  The holiday season is just around the corner, and we invite you to kick it off with us one week from today on Giving Tuesday (Dec 3)! Giving Tuesday is a global day of giving back. On the Tuesday following Thanksgiving, you’ll have the chance to join people around the world and support a[...]

Those of us who already have Darzalex as part of our multiple myeloma treatment will unquestionably be familiar with the term ‘monoclonal antibody’ (mAb). The monoclonals are antibodies that target one specific protein (CD38) that tends to be amply found on the surface of myeloma cells. The rapid growth of the inclusion of Darzalex as[...]

The American Society of Hematology 2019 (ASH) meeting will be held the first week of December. It is the largest meeting in the world on blood cancers. It is very important to know why these outstanding myeloma specialists have chosen these abstracts as the most significant.  The last blog post from Myeloma Crowd’s #ASH19 coverage[...]

  Using the antibiotic levofloxacin prior to stem cell transplant reduces death in newly diagnosed myeloma patients, according to a new study by UK myeloma research collaborators and Myeloma UK.   Infection is the leading cause of death for myeloma patients because the myeloma critically depresses the immune system. In the United Kingdom, there are[...]

Phase III results of a recent study (TOURMALINE-MM4) show that Ninlaro (ixazomib) can prolong survival when used as maintenance therapy for multiple myeloma patients who are not fit enough to receive a stem cell transplant. Ninlaro is in a class of drugs called proteasome inhibitors. Revlimid (lenalomide), an immumomodulator, is commonly used in today’s myeloma[...]

Myeloma Crowd has made it a priority to help the ASH participants interested in multiple myeloma to find the best and most relevant myeloma abstracts from the total of over 1000 myeloma abstracts listed. Each year over 30,000 Doctors, Researchers, Patient Advocates, and Patients attend the ASH conference, and to say it is confusing and overwhelming[...]

The Journal of Oncology Pharmacy Practice published a research paper recently that was quite an eye opener about how well patients with a new diagnosis of a hematological cancer comply with their oral drug regimens. Refills of all oral drugs (oncolytics and non-oncolytics) were tracked for a large number of patients over a period of[...]

Dr. Rafael Fonseca from the Mayo Clinic recently had a conversation Brian McMahon, founder and CEO of SparkCures, about myeloma clinical trials. You can view their interview below, where they discuss the importance of clinical trials, how to search for them, and how to discuss them with your doctors. If you’re interested in finding out[...]

Each year over 30,000 doctors, researchers, patient advocates, and patients attend the American Society of Hematology (ASH) conference. To say it is confusing and overwhelming would be an understatement. There are more than 1925 Oral Abstracts and 4039 Poster Abstracts! How does anyone navigate through the maze to make the best use of their time?[...]